TraceLink.

The largest network you have never logged into

Somewhere right now, a box of medicine is being scanned. A unique serial number pings a cloud, a trading partner three borders away gets a record, and a pharmacist will later confirm that the pills in the bottle are the pills on the label. No human celebrates this. That quiet handshake runs on TraceLink.

TraceLink is the digital connective tissue of the pharmaceutical supply chain. Roughly 280,000 companies - manufacturers, contract packagers, wholesalers, and pharmacies - sit on its network, exchanging the data that proves a drug is what it claims to be and that it traveled the path it was supposed to travel. The company is headquartered in Wilmington, Massachusetts, employs around 850 people, and has raised about $233 million. It is, in the most literal sense, infrastructure.

Infrastructure is rarely glamorous. Nobody tweets about the water main until it bursts. TraceLink has built a business on the same principle: be the thing that does not fail, and let the spotlight go to whoever is launching the next blockbuster drug.

A medicine is only as trustworthy as its paper trail

The pharmaceutical supply chain is a relay race run by strangers. A drug ingredient made in one country becomes a tablet in another, gets packaged by a contractor, sold through a distributor, and dispensed by a pharmacy that has no direct relationship with the factory. Every handoff is a chance for a counterfeit to slip in, a recall to get lost, or a shipment to vanish into a spreadsheet.

For decades the industry tried to solve this with faxes, emails, and trust. The results were predictable. Counterfeit and substandard medicines remain a global problem, and when a batch needs to be pulled, finding every unit can take days that patients do not have.

Regulators eventually agreed. The U.S. Drug Supply Chain Security Act (DSCSA) and the EU's Falsified Medicines Directive turned voluntary good intentions into hard legal requirements: every saleable unit of prescription medicine needs a unique identifier, and partners need to share that data. Suddenly an entire industry needed plumbing it did not have.

Build for the network, not the company

TraceLink began in 2003 in Cambridge, Massachusetts under a different name - SupplyScape - chasing counterfeit drugs with an ePedigree application. That early work helped inform what would become the DSCSA. In 2009, co-founders Shabbir Dahod and Lucy Deus rebuilt the idea as TraceLink, launching a cloud suite for track-and-trace compliance.

The bet was contrarian. Most enterprise software is sold one company at a time, and each buyer integrates in isolation. Dahod's wager was that supply chains are not companies - they are networks - and that the value compounds when a single connection reaches every partner at once. Connect once, reach many. It sounds obvious now. In 2009, asking competitors to share a network was closer to heresy.

Dahod, who studied computer science at Boston University and cut his teeth at Asymetrix - the startup founded by Microsoft's Paul Allen - has run the company as CEO throughout. In 2024 he picked up a Lifetime Achievement Award from Supply & Demand Chain Executive's "Pros to Know," which is the supply chain world's version of a standing ovation.

One network, many jobs

At its core TraceLink does one thing: it lets companies that do not share a database behave as if they do. On top of that foundation it has stacked applications for the specific problems that keep pharma supply chain managers awake.

What can a customer actually do with it? Predict a drug shortage before shelves empty. Pull a recalled batch in hours instead of days. Verify a returned product is genuine. Hand a tedious compliance task to a software agent instead of a stressed analyst. The unglamorous work, done at the scale of an industry.

The numbers do the arguing

Skeptics are right to ask whether "largest network" is marketing or fact. TraceLink's own operating data, reported around the 2025 DSCSA deadline, is specific enough to check.

Backers read the same numbers. Goldman Sachs, FirstMark Capital, Volition Capital, F-Prime Capital, Georgian Partners, Vulcan Capital, and Willett Advisors have all put money in. The Series D alone was $93 million. Third-party estimates put annual revenue in the region of $213 million.

The right medicine, to the right patient

Strip away the platform language and the mission is stubbornly human: make sure the medicine that reaches a patient is safe, real, and available. Visibility, collaboration, and intelligence are the means. A patient who gets the genuine drug, on time, is the end.

It is a mission with a useful side effect - it aligns neatly with regulation. Every new traceability law in every new country is, for TraceLink, both a public-health win and a sales pipeline. The company would surely call that a happy coincidence. Wilde might have called it the rare case of doing well by doing good and not having to choose.

From tracking things to doing the work

The next move is the riskiest. With OPUS Agents, TraceLink is betting that a network of 280,000 connected companies is the natural home for AI agents - software that does not just report a problem but resolves it. A shortage flagged and rerouted. A compliance exception cleared without a human touching it. The network stops being a ledger and starts being a workforce.

Whether the industry trusts autonomous agents with its supply chain is an open question, and a fair one. But TraceLink has a head start most cannot match: it already owns the connections. Agents need a place to act, and the connecting is the hard part. TraceLink did the hard part fifteen years ago.

So return to that scanned box of medicine. A decade ago, the serial number on it would have been a hopeful gesture - a number with nowhere to go. Today it has somewhere to go, and 280,000 companies on the other end ready to read it. Tomorrow, software may act on it before anyone notices there was a decision to make. The handshake stays quiet. That is still the whole point.